One Platform. Smarter IR.

One Platform. Smarter IR.

One Platform. Smarter IR.

Book a Demo

Log in

Book a Demo

Book a Demo

FiskReady

Catch Errors. Build Confidence.

Every press release represents your company to investors, analysts, and the media. A single typo or factual slip can damage credibility. The FiskLabs IR Press Release Reviewer is built to eliminate those risks—delivering polished, accurate releases every time.

LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD’s virtual care platform.

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD’s virtual care platform.

SUMMARY

The release is generally well-structured and contains the required safe-harbor disclaimer, but it includes several promotional statements, an unqualified “fastest-growing” claim, and pricing language that should be qualified. Minor typographic and trademark issues are also present. The boiler-plate is solid, but a media contact line is missing.

The release is generally well-structured and contains the required safe-harbor disclaimer, but it includes several promotional statements, an unqualified “fastest-growing” claim, and pricing language that should be qualified. Minor typographic and trademark issues are also present. The boiler-plate is solid, but a media contact line is missing.

Redlines / Suggested Edits

Redlines / Suggested Edits

Section

Headline

First Paragraph

Current Text

LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients

“... announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy.”

Suggested Revision

No change (clear and factual).

Change “broad, affordable, and streamlined” to “ broad and affordable” (remove “streamlined” / implied.)

Experience next-gen press release accuracy.

See it in Action

See it in Action

LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD’s virtual care platform.

SUMMARY

The release is generally well-structured and contains the required safe-harbor disclaimer, but it includes several promotional statements, an unqualified “fastest-growing” claim, and pricing language that should be qualified. Minor typographic and trademark issues are also present. The boiler-plate is solid, but a media contact line is missing.

Redlines / Suggested Edits

Section

Headline

First Paragraph

Current Text

LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients

“... announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy.”

Suggested Revision

No change (clear and factual).

Change “broad, affordable, and streamlined” to “ broad and affordable” (remove “streamlined” / implied.)

Experience next-gen
press release accuracy.

See it in Action

Raise the Standard

Error-Free Communication
Error-Free Communication

Spot typos, grammar slips, and formatting issues before they go public.

Accuracy
First
Accuracy First

Double-check numbers, dates, tickers, and terminology for consistency with filings.

Professional
Polish
Professional Polish

Ensure your announcements read smoothly and with the credibility investors expect.

Reduced Review
Cycles
Reduced Review Cycles

Minimize back-and-forth between IR, legal, and comms teams.

The FiskReady Advantage

Mistake-Free Announcements

Catch errors before the market does.

Investor-Grade Clarity

Professional tone without fluff or hype.

Peace of Mind

Every release goes out polished, accurate, and aligned.

Consistency Across Releases

Build a reputation for precise, trustworthy communication.

Why Teams Rely on It

No more scrambling after a typo goes live. The IR Press Release Reviewer helps you publish announcements with complete confidence—free of errors, clear in tone, and trusted by investors.
Ensure every release is polished and error-free before it hits the wire.

Book a Demo

Book a Demo

Book a Demo

How it Works

Upload Your Draft
Upload Your Draft

Paste your release in plain text or Word.

Automated Review
Automated Review

The reviewer scans for typos,
misused terms, factual inconsistencies, and readability issues.

Compliance +
Accuracy Checks
Compliance +
Accuracy Checks

Forward-looking statements, safe-harbor language, and key figures are flagged.

Investor-Ready
Output
Investor-Ready
Output

Receive a clean, corrected draft plus notes on any issues found.

Sharper Press Releases, Every Time

Turn every press release into a polished, error-free disclosure.

Learn More

Learn More

Sharper Press Releases, Every Time

Turn every press release into a polished, error-free disclosure.

Learn More